FINWIRES · TerminalLIVE
FINWIRES

Market Chatter: Novo Nordisk Expects Delay for Generic Ozempic in China

By

Novo Nordisk (NVO) expects generic versions of its Ozempic medication to face approval delays in China until next year, Bloomberg News reported Wednesday, citing the drugmaker.

The patent for semaglutide, the main ingredient in Ozempic and Wegovy, expired in China in March, but the company said it still has regulatory data protection until April 2027 due to a trade agreement between China and Switzerland, Bloomberg reported.

Hangzhou Jiuyuan Genetic Biopharmaceutical, the first Chinese firm to seek clearance for a generic, said in March its product review was suspended because of the international data protection stipulations, according to the report.

Novo Nordisk and Hangzhou Jiuyuan did not immediately respond to' requests for comment, while the Chinese regulatory authority could not be reached for comment.

Novo Nordisk shares were more than 3% higher in Wednesday trading.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: $46.21, Change: $+1.34, Percent Change: +2.98%

Related Articles

Wire

Workiva Q1 Adjusted Earnings, Revenue Rise; Shares Drop After Hours

Workiva (WK) reported Q1 adjusted earnings late Tuesday of $0.77 per diluted share, up from $0.14 a year earlier.Analysts polled by FactSet expected $0.65.Revenue for the three months ended March 31 rose to $247.3 million from $206.3 million a year earlier.Analysts surveyed by FactSet expected $245.2 million.Workiva expects Q2 adjusted EPS of $0.62 to $0.65 on revenue of $250 million to $252 million. Analysts expect EPS of $0.52 on revenue of $252.1 million.The company expects full-year adjusted EPS of $2.85 to $2.95 on revenue of $1.037 billion to $1.041 billion. Analysts expect EPS of $2.71 on revenue of $1.038 billion.Workiva shares fell 4.4% in after-hours trading.

$WK
Wire

SSR Mining Q1 Adjusted Earnings, Revenue Rise; Shares Gain After Hours

SSR Mining (SSRM) reported Q1 adjusted earnings late Tuesday of $1.15 per diluted share, up from $0.41 a year earlier.Analysts polled by FactSet expected $0.84.Revenue in the three months ended March 31 rose to $581.8 million from $316.6 million a year earlier.Four analysts surveyed by FactSet expected $536.4 million.SSR Mining shares rose 8% in after-hours trading.

$SSRM
Wire

Everus Construction Q1 Earnings, Revenue Rise; Shares Gain After Hours

Everus Construction Group (ECG) reported Q1 earnings late Tuesday of $1.14 per diluted share, up from $0.72 a year earlier.Analysts surveyed by FactSet expected $0.81.Revenue for the three months ended March 31 rose to $1.04 billion from $826.6 million a year earlier.Analysts polled by FactSet expected $933.8 million.The company raised full-year revenue guidance to $4.3 billion to $4.4 billion from the prior forecast of $4.1 billion to $4.2 billion.Analysts expect $4.23 billion.Everus shares rose 4.2% in after-hours trading.

$ECG